share_log

Sage Therapeutics Expects Cash & Equivalents Plus Funding To Support Its Operations Into 2026; Expects ZULRESSO Revenues To Continue To Decrease Over Time

Benzinga ·  Apr 25 06:40

The Company does not anticipate receipt of any additional milestone payments from collaborations in the remainder of 2024. The Company anticipates operating expenses will decrease in 2024 relative to 2023. With the availability of ZURZUVAE in the U.S. as an additional treatment for women with PPD, the Company anticipates ZULRESSO revenues will continue to decrease over time.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment